FLXN - Flexion Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.24
-0.18 (-1.25%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close14.42
Open14.40
Bid13.66 x 3100
Ask0.00 x 1100
Day's Range13.80 - 14.80
52 Week Range8.76 - 18.93
Volume1,003,616
Avg. Volume632,373
Market Cap542.638M
Beta (3Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-4.28
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.78
Trade prices are not sourced from all markets
  • GlobeNewswire

    Flexion Therapeutics Announces Extended FDA Review of Supplemental New Drug Application for ZILRETTA®

    Flexion Therapeutics, Inc. (FLXN) today announced that the U.S. Food and Drug Administration (FDA) has informed the company it needs additional time to complete the review of the supplemental New Drug Application (sNDA) for ZILRETTA (triamcinolone acetonide extended-release injectable suspension). Although the FDA did not provide a new action date, the FDA informed the company that the review is expected to be completed in the coming weeks. The FDA has not asked for any additional clinical data and the company has provided the FDA with all information requested to date.

  • 3 Top Biotech Stocks With Major Catalysts in October
    TipRanks

    3 Top Biotech Stocks With Major Catalysts in October

    Along with healthcare stocks in general, biotechnology stocks are not hitting any near-term highs in terms of share price performance. Chalk it up to continued fears that the industry will see increased regulation on (largely unfounded) concerns on domestic drug pricing and how to effectively keep citizens with sufficient health insurance while keeping a lid on costs.Regardless of the political climate, drug candidates with proven market potential will always put profits in investor pockets. Below are overviews of three biotech stocks that are far from their 52-week highs and have some potential near-term catalysts. Namely, they have important pending news flow from the Food and Drug Administration (FDA) regarding recent drug applications from their portfolios of promising drug candidates.Agile Therapeutics (AGRX)Agile Therapeutics has finally made it through the late stages of clinical trials for Twirla, its lead product that management is dedicating all of the company’s resources to currently. The latest official status on Twirla is that Agile submitted it for FDA review and received a complete response letter in December 2017. It resubmitted its new drug application (NDA) to the FDA in May of this year, and an advisory committee meeting is scheduled for October 30, followed by PDUFA date on November 16.Twirla is a contraceptive (or more specifically, a low-dose combination hormonal contraceptive, or CHC) patch that, if and once approved, should be much easier to take than daily oral contraceptive pills, which, after many decades, is still the most popular form of birth control. Two of Twirla’s active ingredients are the same that have been used in contraceptives for the past 25 years. Twirla simply requires a weekly patch for three weeks out of every month. Competitors to Twirla include Ortho Evra and its generic equivalent, Xulane, but there is plenty of market share to be taken from the older products.In a research note issued Friday, Maxim analyst Jason McCarthy stated: "Twirla has already received two CRLS, the most recent of which was in December of 2017 and has since been resolved with completion of the adhesion/wear test earlier in 2019. In addition, the company previously completed its third phase 3 trial, the SECURE trial, demonstrating pearl index (PI) and upper bound (UB) 4.8 and 6.06, respectively. The data are in-line with other products recently approved in the space like Slynd demonstrating more 'real-world' PIs and UBs." The analyst concluded, "A combination of activity in the space around contraceptives (regulators too), the steps taken by management to complete clinical work and other requests by regulators and a stronger balance sheet, point to a favorable risk/reward profile."Oppenheimer analyst Leland Gershell shares a similar enthusiasm with McCarthy when it comes to Agile. If the approval plays out as hoped, Gershell sees $261 million in sales by 2024, and pegs Agile’s stock price at $5 per share – well above a current $1.12.Of the five analysts tracked on TipRanks in the past 3 months, the consensus price target is $3.80, which suggests 236% upside from the current share price. Clearly, Agile’s success depend on Twirla, and investors should know later this month what the FDA’s conclusion on the current submission will be. (See Agile stock analysis on TipRanks)Foamix Pharmaceuticals (FOMX)Foamix Pharmaceuticals is also hopeful of getting to market and has two promising late-stage dermatological drugs in its pipeline. FMX101 targets the treatment of moderate-to-severe acne and has already had its NDA submitted. Management is also hopeful to hear some news from the FDA very soon. FMX103 targets moderate-to-severe rosacea, which has much less competition than competing acne treatments in the marketplace. It also made it through clinical three trials and an FDA decision is expected somewhere in the middle of 2020.Cantor analyst Louise Chen reported on Foamix’s presentation at the firm's healthcare conference in early October, noting: "After listening to FOMX's presentation, we continue to look forward to the potential launches of FOMX's two late-stage products in the 2019/20 timeframe. We expect approval for the company's lead product candidate FMX101 for the treatment of moderate-to-severe acne." Chen rates FOMX an Overweight with $15 price target, which implies huge upside to the current share price of $2.80.Research firm Cowen recently pointed out that Foamix is currently building out its sales force in anticipation of the potential launch of both dermatology candidates. Based off its price target of $30, it is effectively twice as bullish as Cantor.Like many development-stage biotech firms, Foamix is in a precarious financial position and has accumulated a deficit above $200 million to bring these and related drugs to market. But with any positive FDA news, the share price will likely soar and open the gateway to plenty of opportunities to raise growth capital.Returning again to TipRanks’ consensus analyst estimates, FOMX has received 3 "buy," ratings in the last three months, while the 12-month average price target lands at $17.00, or more than 500% ahead of the current share price. (See Foamix stock analysis on TipRanks)Flexion Therapeutics (FLXN)Rounding out the trifecta of appealing development-stage biotechs, Flexion just started pulling in sales from the successful launch of Zilretta for the treatment of osteoarthritis, or OA, in patient’s knees. Management has guided full-year sales of between $65 million and $80 million and has pointed out that OA is a type of degenerative arthritis that breaks down and causes the eventual loss of cartilage in the knee joints.Meanwhile, Flexion is awaiting to hear back from the FDA today regarding its supplemental new drug application (sNDA) filing to remove the Limitation of Use (LOU) language from the Zilretta label and marketing materials regarding repeat administration.Wells Fargo analyst David Maris was recently involved with Flexion’s meetings with investors in New York City and detailed that Flexion "continues to remain hopeful and “cautiously optimistic” that the FDA will approve the sNDA and remove the language given the body of data FLXN has generated regarding the safety of Zilretta and its repeat usage. However, FLXN stated that the sNDA is by no means a certainty and it has been scenario planning for all outcomes. In the best-case scenario if the FDA removes the LOU, FLXN stated that it does not expect an immediate inflection in sales but that the removal should provide a tailwind over the longer-term."Maris rates Flexion stock an Outperform, along with a $26 price target, which implies about 95% upside from current levels.Northland Capital's price target is a couple of bucks higher at $28. In a recent report, analyst Carl Byrnes suggested that Flexion’s “current valuation creates a compelling risk/reward scenario as FLXN shares currently trade at ~4.3x consensus 2020 sales, and less than 1x our peak sales forecast.”Profitability isn’t projected until after 2021, but again revenue coming in makes Flexion much more in control of its own destiny. At the end of 2018, accumulated deficit on the balance sheet was $350 million.Rounding out the coverage, the TipRanks universe tracks three analysts (in the past 3 months) with an average price target just shy of $26, or a near double from the current share price of $13.36. (See Flexion stock analysis on TipRanks)

  • Benzinga

    The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings

    Biotech stocks continued to languish for a third straight week. Negative broader market sentiment and company-specific weakness weighed down on the sector. Pfenex Inc (NYSE: PFNX ) received FDA approval ...

  • Do Options Traders Know Something About Flexion Therapeutics (FLXN) Stock We Don't?
    Zacks

    Do Options Traders Know Something About Flexion Therapeutics (FLXN) Stock We Don't?

    Investors need to pay close attention to Flexion Therapeutics (FLXN) stock based on the movements in the options market lately.

  • GlobeNewswire

    Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    The Compensation Committee of the Board of Directors approved the grants with an effective date of October 1, 2019. The stock options and restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $13.47 per share and vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company.

  • Health Check: How Prudently Does Flexion Therapeutics (NASDAQ:FLXN) Use Debt?
    Simply Wall St.

    Health Check: How Prudently Does Flexion Therapeutics (NASDAQ:FLXN) Use Debt?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • GlobeNewswire

    Former NY Yankees Outfielder Chris Dickerson Teams Up With Flexion Therapeutics to Raise Awareness of Impact of Osteoarthritis (OA)

    Flexion Therapeutics (FLXN) is teaming up with Chris Dickerson, a former New York Yankees outfielder and member of the 2011 and 2012 playoff teams, to raise awareness of the impact of osteoarthritis (OA). A degenerative joint disease, OA affects more than 30 million adults living in the U.S. and accounts for more than $185 billion in annual expenditures. With their first playoff game set for this week, Chris’ former teammates in New York are battling a record number of injuries, including many involving debilitating knee pain.

  • GlobeNewswire

    Flexion Therapeutics to Present at the 2019 Cell & Gene Meeting on the Mesa

    Flexion Therapeutics, Inc. (FLXN) announced today that Adam Muzikant, Ph.D., Senior Vice President, Business Development, will present at the annual Cell & Gene Meeting on the Mesa in Carlsbad, California. Dr. Muzikant will provide an overview and update on FX201, Flexion’s preclinical gene therapy product candidate for the treatment of osteoarthritis (OA), on Wednesday, October 2, 2019 at 5:30 p.m. ET (2:30 p.m. PT). Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference featuring more than 80 presentations by leading public and private companies.

  • GlobeNewswire

    Flexion Therapeutics Sponsors a Memorial to the Victims of the Opioid Crisis to Raise Awareness of the Tragic Consequences of the Opioid Epidemic Across the U.S.

    Flexion Therapeutics, Inc. (FLXN), a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), today announced its sponsorship of “Prescribed to Death: A Memorial to the Victims of the Opioid Crisis.” The national traveling exhibit is dedicated to building awareness of the continuing opioid crisis in the United States and was developed by the National Safety Council (NSC) as part of the Stop Everyday Killers public education campaign. The memorial is being presented at the Roosevelt Field Mall in Garden City, NY from September 23-28, 2019 in partnership with Nassau County District Attorney Madeline Singas, Flexion and other regional sponsors.

  • Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
    Zacks

    Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

    Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.

  • Benzinga

    The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ...

  • GlobeNewswire

    Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain

    Flexion Therapeutics, Inc. (FLXN) and Xenon Pharmaceuticals Inc. (XENE) today announced that the companies have entered into a definitive agreement that provides Flexion with the global rights to develop and commercialize XEN402, a NaV1.7 inhibitor, for the management of post-operative pain. The initial development of FX301 is intended to support administration as a peripheral nerve block for control of post-operative pain.

  • Flexion Therapeutics, Inc. (FLXN) Shares March Higher, Can It Continue?
    Zacks

    Flexion Therapeutics, Inc. (FLXN) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Flexion Therapeutics, Inc. (FLXN).

  • Need To Know: Flexion Therapeutics, Inc. (NASDAQ:FLXN) Insiders Have Been Buying Shares
    Simply Wall St.

    Need To Know: Flexion Therapeutics, Inc. (NASDAQ:FLXN) Insiders Have Been Buying Shares

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

  • GlobeNewswire

    Flexion Therapeutics to Present at the Wells Fargo Securities 2019 Healthcare Conference

    BURLINGTON, Mass., Aug. 28, 2019 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate.

  • 3 Healthcare Stocks With Rising Expectations
    Motley Fool

    3 Healthcare Stocks With Rising Expectations

    For a few companies, the second half of 2019 will probably work out better than investors dared hope for earlier this year.

  • Thomson Reuters StreetEvents

    Edited Transcript of FLXN earnings conference call or presentation 6-Aug-19 8:30pm GMT

    Q2 2019 Flexion Therapeutics Inc Earnings Call

  • Flexion Therapeutics, Inc. (FLXN) Q2 2019 Earnings Call Transcript
    Motley Fool

    Flexion Therapeutics, Inc. (FLXN) Q2 2019 Earnings Call Transcript

    FLXN earnings call for the period ending June 30, 2019.

  • Flexion Therapeutics (FLXN) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Flexion Therapeutics (FLXN) Reports Q2 Loss, Tops Revenue Estimates

    Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 9.43% and 20.81%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Flexion Therapeutics Reports Second-Quarter 2019 Financial Results and Recent Business Highlights

    Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $17.0 million in Q2 representing 60% growth over Q1Completed debt.

  • How Should Investors Feel About Flexion Therapeutics, Inc.'s (NASDAQ:FLXN) CEO Pay?
    Simply Wall St.

    How Should Investors Feel About Flexion Therapeutics, Inc.'s (NASDAQ:FLXN) CEO Pay?

    In 2007 Mike Clayman was appointed CEO of Flexion Therapeutics, Inc. (NASDAQ:FLXN). This report will, first, examine...

  • GlobeNewswire

    Flexion Therapeutics to Report Second-Quarter 2019 Financial Results on August 6, 2019

    Flexion Therapeutics, Inc. (FLXN) today announced that it will report its second-quarter 2019 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2019. Flexion Therapeutics (FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. For the past three years, Flexion has been named one of the Best Places to Work by the Boston Business Journal, and Flexion was recognized as a Top Place to Work in Massachusetts by The Boston Globe in 2017 and 2018.